Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-02-12 5:20 pm Purchase |
2020-12-31 | 13G | Chimerix, Inc. CMRX |
Opaleye Management Inc. | 3,956,500 6.320% |
813,600 (+25.89%) |
Filing History |
| 2021-02-12 5:20 pm Purchase |
2020-12-31 | 13G | Infinity Pharmaceuticals, Inc. INFIQ |
Opaleye Management Inc. | 3,171,800 4.940% |
171,400 (+5.71%) |
Filing History |
| 2021-02-12 5:20 pm Purchase |
2020-12-31 | 13G | Adamas Pharmaceuticals, Inc. ADMS |
Opaleye Management Inc. | 1,487,800 5.220% |
61,800 (+4.33%) |
Filing History |
| 2021-02-12 5:20 pm Purchase |
2020-12-31 | 13G | Harrow Health, Inc. HROW |
Opaleye Management Inc. | 3,065,416 11.910% |
3,065,416 (New Position) |
Filing History |
| 2021-02-12 5:20 pm Purchase |
2020-12-31 | 13G | Cardiff Oncology, Inc. CRDF |
Opaleye Management Inc. | 1,662,500 4.710% |
414,500 (+33.21%) |
Filing History |
| 2021-02-12 5:20 pm Sale |
2020-12-31 | 13G | Avenue Therapeutics, Inc. ATXI |
Opaleye Management Inc. | 0 0.000% |
-920 (Position Closed) |
Filing History |
| 2021-02-12 5:20 pm Purchase |
2020-12-31 | 13G | Fortress Biotech, Inc. FBIO |
Opaleye Management Inc. | 259,167 4.150% |
4,160 (+1.63%) |
Filing History |
| 2021-02-12 5:20 pm Purchase |
2020-12-31 | 13G | TRACON Pharmaceuticals, Inc. TCON |
Opaleye Management Inc. | 125,919 17.040% |
125,919 (New Position) |
Filing History |
| 2021-02-12 5:20 pm Purchase |
2020-12-31 | 13G | FS DEV CORP COM FSDC |
Opaleye Management Inc. | 704,400 5.630% |
36,000 (+5.39%) |
Filing History |
| 2021-02-12 5:20 pm Sale |
2020-12-31 | 13G | Semler Scientific, Inc. SMLR |
Opaleye Management Inc. | 290,500 4.360% |
-43,000 (-12.89%) |
Filing History |
| 2021-02-12 5:20 pm Purchase |
2020-12-31 | 13G | Ocular Therapeutix, Inc. OCUL |
Opaleye Management Inc. | 6,510,000 8.650% |
1,384,000 (+27.00%) |
Filing History |
| 2021-01-08 5:28 pm Purchase |
2020-12-30 | 13G | FS DEV CORP COM FSDC |
Opaleye Management Inc. | 668,400 5.340% |
668,400 (New Position) |
Filing History |
| 2020-09-25 5:20 pm Sale |
2020-09-24 | 13D | Protara Therapeutics, Inc. TARA |
Opaleye Management Inc. | 2,508,472 23.860% |
-2,527,538 (-50.19%) |
Filing History |
| 2020-09-18 6:48 pm Purchase |
2020-09-09 | 13G | Infinity Pharmaceuticals, Inc. INFIQ |
Opaleye Management Inc. | 3,000,400 5.100% |
3,000,400 (New Position) |
Filing History |
| 2020-08-31 9:40 pm Purchase |
2020-08-27 | 13G | TRACON Pharmaceuticals, Inc. TCON |
Opaleye Management Inc. | 85,917 13.030% |
85,917 (New Position) |
Filing History |
| 2020-08-28 5:15 pm Purchase |
2020-08-19 | 13G | Cardiff Oncology, Inc. CRDF |
Opaleye Management Inc. | 1,248,000 5.370% |
1,248,000 (New Position) |
Filing History |
| 2020-08-21 5:15 pm Purchase |
2020-08-11 | 13G | Adamas Pharmaceuticals, Inc. ADMS |
Opaleye Management Inc. | 1,426,000 5.040% |
1,426,000 (New Position) |
Filing History |
| 2020-08-21 4:30 pm Purchase |
2020-08-13 | 13G | Chimerix, Inc. CMRX |
Opaleye Management Inc. | 3,142,900 5.140% |
3,142,900 (New Position) |
Filing History |
| 2020-05-26 11:09 am Purchase |
2020-05-14 | 13G | Eton Pharmaceuticals, Inc. ETON |
Opaleye Management Inc. | 2,625,000 10.270% |
285,000 (+12.18%) |
Filing History |